Phase I study to determine the optimal biologic dose of CC-401 in subjects with high-risk myeloid leukemia
Phase of Trial: Phase I
Latest Information Update: 14 May 2007
At a glance
- Drugs CC 401 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
- Focus Adverse reactions
- 31 Oct 2005 New trial record.